Roth Capital set a $6.00 price target on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research report report published on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also recently commented on ATNM. B. Riley set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, August 15th. Maxim Group reaffirmed a buy rating and issued a $3.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, August 14th. Zacks Investment Research cut Actinium Pharmaceuticals from a buy rating to a hold rating in a report on Monday, December 3rd. Finally, Oppenheimer set a $5.00 target price on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 28th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Actinium Pharmaceuticals currently has an average rating of Buy and an average target price of $3.55.

Shares of Actinium Pharmaceuticals stock opened at $0.46 on Tuesday. Actinium Pharmaceuticals has a one year low of $0.33 and a one year high of $0.87.

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC raised its holdings in Actinium Pharmaceuticals by 103.1% during the third quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 99,318 shares during the period. Vanguard Group Inc. raised its holdings in Actinium Pharmaceuticals by 6.4% during the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 154,403 shares during the period. Renaissance Technologies LLC raised its holdings in Actinium Pharmaceuticals by 1,269.5% during the second quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 359,205 shares during the period. PNC Financial Services Group Inc. bought a new stake in Actinium Pharmaceuticals during the third quarter valued at about $617,000. Finally, Essex Investment Management Co. LLC bought a new stake in Actinium Pharmaceuticals during the third quarter valued at about $816,000.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

See Also: Intrinsic Value

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.